证券日报网讯 12月16日，安图生物在互动平台回答投资者提问时表示，报告期内公司取得的3.6亿贷款 为满足临时性资金周转需求，取得的期限不足1年的短期融资业务，截至3季度末相应借款已偿还完毕。 偿还借款支付的现金流请参考"偿还债务支付的现金"项目。 （文章来源：证券日报） ...

郑州海关统计处相关负责人介绍称，该服务自今年12月15日起已在全国海关全面实施。企业单次查询时 间跨度不超过3个月，普通企业每日每次最多可查询50个报关单号，高级认证企业则无限额，海关对诚 信企业具有激励导向。 近年来，郑州海关持续推进智慧海关建设，该措施是深化"放管服"改革、优化跨境贸易营商环境的关键 一环。郑州海关方面表示，未来将进一步降低外贸企业制度性交易成本，提升企业在国际竞争中的敏捷 性与竞争力。(完)【编辑:惠小东】 "过去打印盖章报关单，得跑海关业务现场。现在只需在电脑前操作，二十分钟左右就能批量完成，省 时又便捷！"上述企业国际商务部经理李畅表示，其主要出口体外诊断试剂与仪器，以往为评估货物出 口情况，常需派人前往多个申报地海关调取打印纸质单证，流程往往耗时2至4个工作日，现在可随时查 询下载，实现了数据获取的即时化、精准化和便捷化。 中新网郑州12月16日电(阚力 张楠)郑州海关16日消息称，河南省首份报关单证自助打印落地，外贸企业 迎来"足不出户、随时获取"的单证管理新体验。 这份由郑州安图生物工程股份有限公司通过"中国国际贸易单一窗口"标准版网站的"报关单证自助查询 打印"模块，成功自助 ...

Core Viewpoint - Antu Biology (603658) acknowledges that its stock price in the secondary market is influenced by various factors including industry policies, macroeconomic environment, capital market supply, and investor risk appetite [1] Group 1 - The company is highly attentive to stock price performance and shareholder concerns [1] - Antu Biology continues to focus on its core business development and emphasizes product research and development [1] - The company is committed to improving operational quality and actively communicates with the market through compliant channels to protect the long-term interests of all shareholders [1]

证券日报网讯 12月16日，安图生物在互动平台回答投资者提问时表示，公司仪器核心产品运维由公司 的客服团队负责，客服人员根据专业构成在年报中包含在销售人员里。 （文章来源：证券日报） ...

证券日报网讯 12月16日，安图生物在互动平台回答投资者提问时表示，面对复杂的呼吸道感染病原 体，公司依托自身的技术研发与生产体系，构建了覆盖"精准诊断、快速筛查、便捷普查"的全场景、多 技术平台呼吸道病原体检测方案，为临床提供精准的诊断武器。2025年呼吸道分子系列同比增长13%， 磁微粒呼吸道整体同比增长3%。同时，公司的居家胶体金快速检测试剂甲型流感病毒、乙型流感病 毒、腺病毒和呼吸道合胞病毒获批上市，其中，腺病毒和呼吸道合胞病毒抗原检测试剂盒，是国内首批 获批的可用于消费者居家自测的检测试剂产品，填补了国内这两类病毒居家自测领域的空白。公司海外 流感相关产品为磁微粒平台产品，目前销量较为平稳，胶体金快速检测类产品海外暂未开始注册。 （文章来源：证券日报） ...

Core Viewpoint - Antu Biology has achieved a significant breakthrough in gene detection with the approval of its Sikun series gene sequencers, marking a strategic shift from traditional biochemical detection to precision diagnostics [1][3]. Company Developments - Antu Biology's Sikun series gene sequencers (Sikun2000, Sikun1000, Sikun500) received medical device registration certificates from the National Medical Products Administration, allowing them to enter the clinical testing market, with an expected launch in January 2026 [1]. - The company emphasizes that this is its first sequencing instrument registration certificate, which is strategically important for its development [1]. - The Sikun series is fully self-developed and utilizes reversible terminator technology, facilitating a smooth transition for medical institutions while ensuring data quality and reducing labor and time costs [1]. Industry Insights - The gene testing market in China has shown continuous growth, with the market size increasing from 7.2 billion yuan in 2016 to an expected 37.4 billion yuan by 2024, and projected to reach 153.6 billion yuan by 2030, reflecting a compound annual growth rate of 25.8% over the next five years [2]. - The introduction of Antu Biology's three new products increases the total number of gene sequencers in the domestic market to ten, contributing to the upgrade of the domestic sequencing industry and accelerating the process of domestic substitution [2]. - The core components of the three products are entirely self-developed, moving away from the OEM model, which stabilizes the supply chain and enhances cost-effectiveness, while also driving the upgrade of upstream and downstream industries [3].

Group 1 - The company plans to use idle raised funds for cash management, ensuring it does not affect the normal implementation of fundraising projects and guarantees the safety of the raised funds [3][11][19] - The investment types include structured deposits, large certificates of deposit, reverse repos, broker income certificates, and broker wealth management products, all of which are high-security and liquid principal-protected products [2][7][8] - The total investment amount will not exceed 1.4 billion yuan from publicly issued convertible bonds and 15.4 billion yuan from non-publicly issued stock [2][4][7] Group 2 - The cash management is aimed at enhancing the value of idle funds and increasing company revenue while protecting the interests of all shareholders [3][19] - The board of directors approved the cash management proposal on December 9, 2025, during the ninth meeting of the fifth board [13][30] - The cash management products will be managed by reputable financial institutions that provide principal protection, and the investment period will not exceed 12 months [8][9][30] Group 3 - The company will ensure that the cash management does not affect the normal operations and funding needs of the company [19][33] - The financial products will be recorded as trading financial assets or other current assets in the balance sheet, with interest income recorded in the profit statement [19][33] - The company will disclose cash management details in accordance with relevant regulations and guidelines [12][32]

Group 1 - AnTu Biologics (SH 603658) announced on December 9 that its fifth board meeting was held to discuss the use of idle fundraising for cash management [1] - For the year 2024, AnTu Biologics' revenue composition is 98.17% from in vitro diagnostics and 1.83% from other businesses [1] - As of the report, AnTu Biologics has a market capitalization of 20.4 billion yuan [1]

证券代码：603658 证券简称：安图生物 公告编号：2025-083 郑州安图生物工程股份有限公司 关于使用闲置自有资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、本次使用闲置自有资金进行现金管理的情况概述 （一）现金管理目的 投资种类：安全性高、流动性好、风险可控的金融产品 投资金额：不超过 26 亿元闲置自有资金 投资期限：董事会审议通过之日起一年之内有效 已履行的审议程序：郑州安图生物工程股份有限公司（以下简称"公司"）于 2025 年 12 月 9 日召开第五届董事会第九次会议，审议通过了《关于使用闲 置自有资金进行现金管理的议案》。 特别风险提示：公司购买的金融产品都需要经过严格的评估，但金融市场受 宏观经济的影响较大，不排除该项投资受到市场波动的影响。公司将根据经 济形势以及金融市场的变化适时适量地介入，因此短期投资的实际收益不可 预期。 现金管理，用于购买安全性高、流动性好、风险可控的金融产品。在上述额度范围 内，资金可在12个月内滚动使用。 （三）资金来源 公司及控 ...

招商证券股份有限公司 关于郑州安图生物工程股份有限公司 使用闲置募集资金进行现金管理的核查意见 招商证券股份有限公司（以下简称"招商证券"或"保荐机构"）作为郑州 安图生物工程股份有限公司（以下简称"安图生物"或"公司"）非公开发行股 票的保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司募集资金监 管规则》《上海证券交易所股票上市规则》《上海证券交易所上市公司自律监管指 引第 1 号——规范运作》《上海证券交易所上市公司自律监管指引第 11 号——持 续督导》等相关法律、法规和规范性文件的规定，对安图生物使用闲置募集资金 进行现金管理的事项进行了核查，发表如下核查意见： 一、现金管理情况概述 （一）现金管理目的 本次现金管理是在确保不影响募投项目正常实施、保证募集资金安全的前提 下使用部分暂时闲置募集资金进行的，可以更好地实现公司募集资金的保值增值， 增加公司收益，维护公司全体股东的利益。 （二）现金管理金额 不超过1.4亿元公开发行可转换公司债券闲置募集资金和不超过15.4亿元非 公开发行股票闲置募集资金。 （三）资金来源 1．公司公开发行可转换公司债券闲置募集资金： | 发行名称 | 2019 | ...